The IV Consortium Meeting of MOPEAD is held in September
The team of researchers that makes up the European research project MOPEAD (Models of Patient Engagement for Alzheimer 's Disease), led by Mercè Boada, medical director at Fundació ACE, will meet on 12th -13th September in the IV Consortium Meeting that will take place in Barcelona, at the headquarters of the Foundation. The study aims to consolidate a system of early detection of Alzheimer's through the participation of the citizens.
MOPEAD, which has a budget of 4,086 million euros, is an innovative initiative born from the experience of the Memory Unit of Fundació ACE in actions to detect low cognitive and memory deficits among the population. The project wants to evaluate different systems to increase the participation of patients that may be effective for the early detection of Alzheimer's. In addition, MOPEAD also wants to contribute to raise awareness about the disease and the importance of research in order to identify unknown cases, as well as to contribute with new clinical data in order to find tools and therapeutic interventions to stop Alzheimer's.
The study, coordinated by Fundació ACE, is a multicentric project participated by a consortium of public and private institutions of 5 European countries: Germany, Slovenia, Spain, the Netherlands and Sweden. It is also supported by the IMI (Innovative Medicines Initiative), a public-private consortium between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA), as well as the pharmaceutical companies Eli Lilly and AstraZeneca.
If you want to know more about the reason why of MOPEAD, click here.
